Evidence map›Paper›PMID 36556362›Full record

ArticleLife (Basel, Switzerland)2022

Total Facial Autologous Fat Grafting for Treating Skin Manifestations in Scleroderma.

Ariel Berl, Ofir Shir-Az, Noa Perk, Abraham Levy, Yair Levy, Avshalom Shalom

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Treatable Traits in Systemic Sclerosis.Clinical reviews in allergy & immunology · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ariel BerlDepartment of Plastic Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.ORCID 0000-0003-3705-5454
Ofir Shir-AzDepartment of Plastic Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.ORCID 0000-0001-7942-6394
Noa PerkDepartment of Plastic Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.
Abraham LevyDepartment of Plastic Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.
Yair LevySackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Avshalom ShalomDepartment of Plastic Surgery, Meir Medical Center, Kfar Saba 4428164, Israel.
Tel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) or scleroderma, is a rare, systemic autoimmune connective tissue disease that can cause fibrosis of cutaneous tissue and visceral organs. Facial involvement can have a deleterious effect on patients' function, cosmetic appearance and quality of life. This study describes our experience and results with total facial autologous fat grafting for treating scleroderma. It includes 14 women and 3 men with SSc, at an average age of 51.3 years who underwent 32 autologous fat grafting surgeries between 2017-2022. The surgical technique is further described and demographic and surgical data, including preoperative and postoperative measurements were analyzed. Patients who had multiple surgeries ultimately received grafts with twice the volume of fat than in the first procedure. The oral opening increased an average of 33%. All patients reported improvement in quality of life and were very satisfied with the aesthetic outcomes. The use of autologous fat grafting to treat SSc patients successfully increased oral openings and improved facial manifestations. The procedure is reproducible, safe and leads to improvement in facial manifestations and patients' quality of life. It can be repeated over time to preserve or enhance the results.

Indexed as

adipose-derived stem cellsautologous fat graftingsclerodermasystemic sclerosis (SSc)

Identifiers

PMID36556362
PMCPMC9783901
OpenAlexW4311003710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.